Inhibition of protein kinase Cβ prevents foam cell formation by reducing scavenger receptor A expression in human macrophages

Circulation

Volumn 118, Issue 21, 2008, Pages 2174-2182

  Osto, Elena ^a   Kouroedov, Alexei ^a   Mocharla, Pavani ^a   Akhmedov, Alexander ^a   Besler, Christian ^a   Rohrer, Lucia ^b   Von Eckardstein, Arnold ^b   Iliceto, Sabino ^c   Volpe, Massimo ^d,e   Lüscher, Thomas F ^a   Cosentino, Francesco ^a,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Atherosclerosis; Foam cells; Lipoproteins, LDL; Macrophages; Protein kinase C; Receptors, scavenger

Indexed keywords

4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; CD14 ANTIGEN; CHLORDANE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LY 379196; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA INHIBITOR; SCAVENGER RECEPTOR A; SMALL INTERFERING RNA; SUPEROXIDE; THREONINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; ENZYME INHIBITION; FLOW CYTOMETRY; FOAM CELL; HUMAN; HUMAN CELL; INCUBATION TIME; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; UPREGULATION;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; CARCINOGENS; CELL LINE; FOAM CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MACROPHAGE ACTIVATION; MESYLATES; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; RNA, SMALL INTERFERING; SCAVENGER RECEPTORS, CLASS A; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57449106477     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.789537     Document Type: Article

References (38)

1. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999;13:1658-1676.
2. Edwards AS, Faux MC, Scott JD, Newton AC. Carboxyl-terminal phosphorylation regulates the function and subcellular localization of protein kinase C betaII. J Biol Chem. 1999;274:6461-6468.
3. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-2588.
4. Inoguchi T, Battan R, Handler E, Sportsman JR, Heath W, King GL. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A. 1992;89:11059-11063.
5. Beckman JA, Goldfine AB, Gordon MB, Garrett LA, Creager MA. Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. Circ Res. 2002;90:107-111.
6. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation. 2003;107:1017-1023.
7. Kouroedov A, Eto M, Joch H, Volpe M, Luscher TF, Cosentino F. Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 2004;110:91-96.
8. Birch KA, Heath WF, Hermeling RN, Johnston CM, Stramm L, Dell C, Smith C, Williamson JR, Reifel-Miller A. LY290181, an inhibitor of diabetes-induced vascular dysfunction, blocks protein kinase C-stimulated transcriptional activation through inhibition of transcription factor binding to a phorbol response element. Diabetes. 1996;45:642-650.
9. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett. 2003;13:1857-1859.
10. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro- 4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem. 1996;39:2664-2671.
11. Campochiaro PA, for the C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45:922-931.
12. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C Beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188-2197.
13. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci. 2006;47:86-92.
14. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care. 2005;28:2686-2690.
15. Vinik A. The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. Expert Opin Investig Drugs. 2005;14:1547-1559.
16. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:487-496.
17. Llaverias G, Noe V, Penuelas S, Vazquez-Carrera M, Sanchez RM, Laguna JC, Ciudad CJ, Alegret M. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun. 2004;318:265-274.
18. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
19. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia. 2001;44:659-673.
20. Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res. 2004;94:892-901.
21. Ward NE, O'Brian CA. Inhibition of protein kinase C by N-myristoylated peptide substrate analogs. Biochemistry. 1993;32:11903-11909.
22. Spiekermann S, Landmesser U, Dikalov S, Gamez G, Talge H, Hornig B. Drexler H, Harrison DG. Electron spin resonance characterization of vascular NAD(P)H- and xanthine-oxidase-activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation. 2003;107:1383-1389.
23. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev. 2003;83:1069-1112.
24. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235-1242.
25. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, Rhee JS, Silverstein R, Hoff HF, Freeman MW. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem. 2002;277:49982-49988.
26. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res. 2000;41:688-696.
27. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
28. Kosswig N, Rice S, Daugherty A, Post SR. Class A scavenger receptor-mediated adhesion and internalization require distinct cytoplasmic domains. J Biol Chem. 2003;278:34219-34225.
29. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol. 2002;160:2145-2155.
30. Ricci R, Sumara G, Sumara I, Rozenbcrg I, Kurrer M, Akhmedov A, Hersberger M, Eriksson U, Eberli FR, Becher B, Boren J, Chen M, Cybulsky MI, Moore KJ, Freeman MW, Wagner EF, Matter CM, Luscher TF. Requircmenl of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science. 2004;306:1558-1561.
31. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy, part I. Circulation. 2003;108:1527-1532.
32. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S. Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R, Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodenl model for type 2 diabetes. FASEB J. 2000;14:439-447.
33. Avignon A, Sultan A, PKC-B inhibition: a new therapeutic approach for diabetic complications? Diabetes Metab. 2006;32:205-213.
34. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000;49:1939-1945.
35. Gordon S. Macrophage-restricted molecules: role in differentiation and activation. Immunol Lett. 1999;65:5-8.
36. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, Tarakhovsky A. Immunodeficiency in protein kinase Cbeta-deficient mice. Science. 1996;273:788-791.
37. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272:728-731.
38. Idris I, Gray S, Donnelly R. Protein kinase C-beta inhibition and diabetic microangiopathy: effects on endothelial permeability responses in vitro. Eur J Pharmacol. 2004;485:141-144.